Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.56 |
| ▸ | SETD2 | Q9BYW2 | 19/20 | 0.52 |
| ▸ | NSD2 | O96028 | 4/20 | 0.51 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.47 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | HTR1B | P28222 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30471285 | 0.89 | IDO1 (0.54) | HRH4SETD2NSD2 | |
| SCHEMBL25039711 | 0.88 | HRH4 (0.56) | HRH4SETD2NSD2CYP2C8DRD2 | |
| SCHEMBL21739348 | 0.86 | HRH4 (0.54) | HRH4SETD2NSD2CYP2C8DRD2 | |
| SCHEMBL21725077 | 0.82 | HRH4 (0.59) | HRH4SETD2NSD2 | |
| SCHEMBL30056140 | 0.82 | HRH4 (0.59) | HRH4SETD2NSD2 | |
| SCHEMBL21724765 | 0.81 | HRH4 (0.58) | HRH4SETD2NSD2CYP2C8DRD2 | |
| SCHEMBL30544767 | 0.79 | PTPN11 (0.41) | HRH4SETD2NSD2 | |
| SCHEMBL25812184 | 0.78 | ALOX15 (0.50) | HRH4SETD2NSD2 | |
| SCHEMBL25040426 | 0.77 | SETD2 (0.60) | HRH4SETD2NSD2CYP2C8DRD2 | |
| SCHEMBL26097856 | 0.77 | SETD2 (0.60) | HRH4SETD2NSD2CYP2C8DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230049113-A1 | METHODS OF TREATING WHSC1-OVEREXPRESSING CANCERS BY INHIBITING SETD2 | Epizyme, Inc. | 2023-02-16 | — | — | US | disclosed |
| WO-2020112872-A1 | METHODS OF TREATING WHSC1-OVEREXPRESSING CANCERS BY INHIBITING SETD2 | Epizyme, Inc. (US) | 2020-06-04 | — | — | WO | disclosed |
| WO-2020037079-A1 | SUBSTITUTED INDOLES AND METHODS OF USE THEREOF | Epizyme, Inc. (US) | 2020-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230049113-A1 | METHODS OF TREATING WHSC1-OVEREXPRESSING CANCERS BY INHIBITING SETD2 | NSD1, NSD3, EHMT1 | HRH4 3748/4885SETD2 8/4885NSD2 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.